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Abstract
Background:  Complications of chronic kidney disease (CKD) contribute to morbidity and
mortality. Consequently, treatment guidelines have been developed to facilitate early detection and
treatment. However, given the high prevalence of CKD, many patients with early CKD are seen by
non-nephrologists, who need to be aware of CKD complications, screening methods and
treatment goals in order to initiate timely therapy and referral.
Methods: We performed a web-based survey to assess perceptions and practice patterns in CKD
care among 376 family medicine and internal medicine trainees in the United States. Questions
were focused on the identification of CKD risk factors, screening for CKD and associated co-
morbidities, as well as management of anemia and secondary hyperparathyroidism in patients with
CKD.
Results: Our data show that CKD risk factors are not universally recognized, screening for CKD
complications is not generally taken into consideration, and that the management of anemia and
secondary hyperparathyroidism poses major diagnostic and therapeutic difficulties for trainees.
Conclusion: Educational efforts are needed to raise awareness of clinical practice guidelines and
recommendations for patients with CKD among future practitioners.
Background
Complications of chronic kidney disease (CKD), such as
anemia, metabolic acidosis, nutritional deficits, second-
ary hyperparathyroidism and hypertension occur well
before renal replacement therapy is needed and signifi-
cantly contribute to morbidity and mortality [1-5].
National treatment guidelines for CKD, and for the man-
agement of hypertension, dyslipidemia, bone disease,
nutrition, anemia and cardiovascular disease in patients
with CKD, have been published [6-12], and dedicated
CKD clinics were established based on the conviction that
such clinics would help implement Kidney Disease Out-
comes Quality Initiative (KDOQI) goals and thus
improve outcomes [13,14]. This belief was supported by
the observation that patients with already-established
advanced CKD who were referred late to a nephrologist
had worse outcomes than those referred earlier [15,16],
and several groups of researchers [17-20] have postulated
that CKD care could be improved by early detection, early
referral, and a structured approach to CKD care. An anal-
ysis based on the National Health and Nutrition Examina-
tion Surveys (NHANES) III and Medicare databases
showed that CKD care is suboptimal [21], and recent data
suggests that primary care providers may not be familiar
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will KDOQI guidelines [22]. However, given the vast
number of patients with CKD and the limited number of
nephrologists [23,24], most patients with early CKD are
not seen by a nephrologist. Therefore, this web-based sur-
vey was designed to ascertain perceptions and practice
patterns regarding CKD care in family medicine and inter-
nal medicine trainees.
Methods
Study design
The study was approved by the University of Miami's
Human Subjects Research Office, protocol number
20060089, under the exempt category. This is a cross-sec-
tional survey of family medicine and internal medicine
trainees in the United States, conducted in February and
March 2006. Attending physicians' responses served as a
control group. The survey was designed to test practice
patterns and was based on current KDOQI recommenda-
tions.
Population
Interns, residents, and fellows who were in training in
family medicine or internal medicine residency programs
in February or March 2006 within the United States were
targeted for this survey. A group of attending physicians
was included as a control group based on the hypothesis
that their responses would provide an insight into the
expected knowledge level of trainees at the end of their
training.
Inclusion criteria
Physicians were included in the survey if they identified
themselves as physicians practicing family or internal
medicine.
Exclusion criteria
Excluded were respondents other than physicians (such as
nurses or students), respondents whose primary specialty
was not family or internal medicine, and respondents
who did not provide any answer apart from demograph-
ics.
Survey method
The online survey instrument was critically reviewed by
four experts in the field, administered to a focus group of
five family medicine residents, and modified according to
their suggestions. The survey was conducted in an anony-
mous fashion; no identifying data were retained. The
sequence in which choices were presented for questions
with multiple answers was randomized for each respond-
ent. All answers except those about age and gender were
required to advance in the survey. The survey instrument
was posted online on February 1, 2006. Invitations to par-
ticipate in the survey were distributed by email between
February 17, 2006 and March 1, 2006 to 710 internal
medicine and family medicine program directors across
the United States. It was left up to the program director to
decide whether or not to forward the invitation email to
residents. A similar email was sent to attending physicians
at the PI's center (University of Miami Miller School of
Medicine, Miami, FL, USA) on March 3, 2006. The survey
instrument was open for responses from February 17,
2006 to March 16, 2006. No incentive was offered for
completion of the survey. A copy of the survey instrument
is enclosed in  Additional file 1. We also surveyed ten
nephrology fellows and attendings to have an internal
"positive control", and the data they provided are
enclosed in  Additional file 2.
Statistical analysis
Data are presented as descriptive statistics derived from
cross-tabulation. Proportions were calculated based on
the total number of respondents for each question and
compared using Fisher's exact test assuming a normal dis-
tribution. Questions about risk factors were dichotomized
into two groups, with those responding that the individ-
ual risk factor highly increases risk coded as yes and those
responding that it does not or slightly increases risk coded
as no. All analyses were carried out using SPSS 14.0 for
Windows (SPSS Inc., Chicago, IL, USA). Area proportional
Venn diagrams were constructed using the web-based
application developed by S. Chow and P. Rodgers [25,26].
Results
Study population
A total of 463 responses were received. A response rate
could not be calculated given that the target population
was not queried directly but through program directors.
Fifty-one datasets were blank and were discarded; the
remaining 412 data sets were retained for analysis. One
hundred and sixty-two responses were received from fam-
ily medicine trainees, 214 from internal medicine train-
ees, and 36 from attending physicians. Of the latter group,
six were family practitioners, and 30 were internists.
Among the internists there were one endocrinologist, one
gerontologist, one oncologist, three infectious disease
specialists, six cardiologists, and 18 general internists.
Both trainees and attending physicians reported seeing a
median of six patients with chronic kidney disease per
week.
Recognition of risk factors for chronic kidney disease and 
assessment of kidney function
Participants were asked to rank a set of factors as increas-
ing the risk for CKD "minimally", "moderately", or
"highly". Answers were dichotomized, with "highly"
being categorized as "yes" and the other two options as
"no". The results are shown in Figure 1. The responses by
family medicine and internal medicine trainees were not
significantly different, and thus their responses wereBMC Medicine 2006, 4:30 http://www.biomedcentral.com/1741-7015/4/30
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pooled. Compared to trainees, a significantly higher pro-
portion of attendings identified African-American race as
a high risk to develop CKD (p < 0.005).
Participants were asked to identify the best method to esti-
mated kidney function (Figure 2). Timed urine collection
for creatinine was the most common choice, followed by
estimated glomerular filtration rate (eGFR) using a math-
ematical formula. Compared to family medicine resi-
dents, a significantly higher proportion of internal
medicine trainees, but not attending physicians, preferred
eGFR over measured creatinine clearance (p < 0.0001).
Blood pressure goal and therapy choices
The vast majority of respondents chose a blood pressure
goal of less than 130/80 mmHg for a hypothetical patient
with CKD and a creatinine clearance of 40 ml/min (Figure
3A). The question posed was: "Which class of antihyper-
tensive medication was considered a first-line agent to
slow the progression of kidney disease in a patient with
mild to moderate CKD?" (Figure 3B). The responses from
family medicine trainees, internal medicine trainees, and
attendings were not statistically different for the data
shown in Figures 3A,B, and were therefore pooled. Angi-
otensin-converting enzyme inhibitors (ACEi) or angi-
otensin receptor blockers (ARB) were the first-line
medications chosen by 90% and 48% of respondents,
respectively, and only 6% chose neither of the two.
Respondents were then given a case scenario of a 37-year-
old man with hypertension, microalbuminuria, and a
blood pressure of 145/95 mmHg, who is only treated with
a thiazide diuretic. Asked if they would add an ACEi to
this patient's regimen, a decreasing number of respond-
ents opted to do so as the patient's serum creatinine
increased (Figure 3C). Family medicine trainees were sig-
nificantly less likely to choose an ACEi once the serum cre-
atinine was greater than 1.4 mg/dl (P < 0.0001). There was
no difference in the response whether the scenario was
given for an African-American or a Non-Hispanic Cauca-
sian man (data not shown).
Identification of risk factors for CKD Figure 1
Identification of risk factors for CKD. Shown is the pro-
portion of respondents who stated that the shown condi-
tions "highly" increase the risk to develop chronic kidney 
disease. HTN: hypertension. **p < 0.005 (all trainees versus 
attendings).
Evaluating kidney function Figure 2
Evaluating kidney function. Shown is the proportion of 
respondents who identified serum creatinine, measured cre-
atinine clearance, or estimated glomerular filtration rate 
(GFR), respectively, as the best method to evaluate kidney 
function. **p < 0.005; ***p < 0.0005 (family medicine versus 
internal medicine trainees).BMC Medicine 2006, 4:30 http://www.biomedcentral.com/1741-7015/4/30
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Complications of CKD
When asked what conditions were complications of CKD,
more than 80% of all respondents recognized worsening
hypertension, anemia, hyperkalemia, and volume over-
load. A smaller proportion of family medicine residents
than internal medicine trainees chose metabolic acidosis
(76% vs 85%, P < 0.05) and secondary hyperparathy-
roidism (SHP; 61% vs 86%, P < 0.0001). A smaller pro-
portion of trainees identified malnutrition (47% and
54%) and dyslipidemia (32% and 42%) as CKD compli-
cations. The proportion of attendings was higher than the
proportion of trainee for any of the choices (Figure 4A). A
case scenario of a 55-year-old African-American woman
with hypertension, type 2 diabetes, and a last known
serum creatinine of 2 mg/dl, was given. The question was
posed: "Which of the following laboratory tests would
you order in a patient like this?" in order to determine
what complications trainees were likely to screen for (Fig-
ure 4B). Seventy percent of all respondents requested
microalbumin in a random urine sample, but only 19%,
37%, and 23% of family medicine trainees, internal med-
icine trainees and attendings, respectively, concomitantly
requested a urine creatinine. Although more than 80% of
trainees identified anemia as a complication of CKD, only
36% requested a complete blood count in this hypotheti-
cal patient with stage 3 CKD. Screening for SHP and nutri-
tion reflected the low rates of recognition shown in the
prior question (Figure 4A). Moreover, when screening for
SHP, 10%, 21% and 20% of family medicine trainees,
internal medicine trainees, and attendings, respectively,
only requested serum calcium and serum phosphate, and
only 6%, 19%, and 23%, respectively, requested a parath-
yroid hormone (p = 0.002 for family versus internal med-
icine trainees), either alone (1%, 5%, 10%) or together
with calcium and phosphate (5%, 14%, 13%). All except
two attendings (94%) indicated that they would request
A1c, while only 74% of trainees did so (P < 0.0005). A
similar discrepancy between attendings and trainees was
seen for the lipid panel (75% vs 48%, p < 0.005).
Anemia and secondary hyperparathyroidism
Three additional questions concerning screening and
management of anemia and SHP were posed: (1) is it a
complication of CKD;(2) at what stage of CKD do you
screen for it; and (3) at what level of hemoglobin (Hgb)
or parathyroid hormone (PTH), respectively, do you start
therapy or ask for a consultation when faced with a
patient whose creatinine clearance is 40 ml/min. Only
respondents who answered all three questions were
included in the analysis (N = 312). Data from all respond-
ents, family and internal medicine trainees and attend-
ings, were pooled for this analysis and represented as area
proportional Venn diagrams (Figure 5). In each diagram,
area A represents the proportion of respondents who
identified the condition as a complication of CKD, area B
Blood pressure management in CKD patients Figure 3
Blood pressure management in CKD patients. Panel A 
shows the blood pressure goals chosen for patients with 
stage 3 CKD. Panel B shows the classes of antihypertensive 
agents identified as first-line therapy to slow the progression 
of renal failure in patients with mild to moderate renal 
impairment. For panels A and B, data were pooled from all 
respondents as no differences were found between trainees' 
or attendings' responses. Panel C shows the proportion of 
respondents who would add an angiotensin converting 
enzyme inhibitor to the regimen of a hypertensive patient 
with microalbuminuria currently treated with a thiazide diu-
retic, as a function of the patient's serum creatinine. ***p < 
0.005 for family medicine versus internal medicine trainees 
and p < 0.05 for family medicine trainees versus attendings. p 
> 0.05 for internal medicine trainees versus attendings.BMC Medicine 2006, 4:30 http://www.biomedcentral.com/1741-7015/4/30
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indicates the proportion of respondents screening for the
condition in stage 3 CKD or earlier, and area C shows the
proportion of respondents who started therapy or asked
for a consult at a Hgb < 11 g/dl or a PTH >70 ng/ml,
respectively. Among all respondents, 92% identified ane-
mia as a complication of CKD, 55% indicated that they
would screen at stage 3 CKD or earlier, and 15% would
intervene at a hemoglobin of less than 11 g/dl in a patient
with a creatinine clearance of 40 ml/min, resulting in only
11% of respondents who correctly integrated all three
parameters. Similar results were seen for SHP manage-
ment, with only 15% of respondents identifying SHP as a
CKD complication, screening at CKD stage 3 or earlier,
and intervening once intact PTH surpasses 70 ng/ml in a
patient with a creatinine clearance of 40 ml/min.
Discussion
Delayed referral of CKD patients to a nephrologist has
been identified as an important predictor of poor out-
comes [15,16]. However, in order to initiate timely refer-
ral of CKD patients, primary providers need to be aware of
risk factors for CKD and co-morbidities associated with
CKD, as well as clinical practice guidelines describing
optimal CKD care, such as KDOQI guidelines, the
recently-published recommendations from the American
Diabetes Association (ADA) [27], or the clinical practice
guidelines developed by the Renal Physicians Association
[28], the latter being published as an executive summary
with clear "hands-on" guidance as to the management of
patients with an estimated GFR of less than 30 ml/min/
1.73 m2. Several educational efforts are currently under
way to enhance awareness of CKD [29,30]. However, the
data presented in this report show that both family medi-
cine and internal medicine trainees have important
knowledge gaps when it comes to CKD care.
Similar to data recently published by Lea et al [22], almost
all physicians identified diabetes and hypertension as
strong risk factors, while minority status or family history
did not receive the same recognition. This may be due to
the absence of a unifying model predicting CKD risk in
the general population [31]. Some risk factors, such as
diabetes and hypertension, have clearly been established
[32]. However, attempts to quantitate the contribution of
others, such as race, ethnicity, and socio-economic status,
has proven to be more challenging because of the varying
prevalence of co-morbid diseases such as hypertension
[33-35]. In addition, the prevalence of CKD among differ-
ent racial and ethnic groups may vary according to the
stage of CKD [36]. Thus, it may be necessary to perform
and pool data from large, population-based studies to fur-
ther delineate the contribution of individual CKD risk fac-
tors [37,38], allowing primary providers to screen for
CKD akin to cardiovascular risk assessment based on the
Framingham Study [39].
Complications of CKD Figure 4
Complications of CKD. Panel A shows the proportion of 
respondents who identified the listed conditions as co-mor-
bidities of CKD (*p < 0.05; **p < 0.01; ***p < 0.005 for train-
ees versus attendings). Panel B shows the proportion of 
respondents who would order the listed laboratory data in a 
hypothetical patient (55 year-old African American woman 
with diabetes, hypertension, and a serum creatinine of 2 mg/
dl). Data for family medicine and internal medicine were 
pooled because the two groups were not different from each 
other. **p < 0.01 for trainees versus attendings.BMC Medicine 2006, 4:30 http://www.biomedcentral.com/1741-7015/4/30
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Management of anemia and secondary hyperparathyroidism Figure 5
Management of anemia and secondary hyperparathyroidism. The top panel shows the proportion of respondents 
who indicated that anemia is a complication of CKD (A, 92%), that they screened starting in stage 3 CKD or earlier (B, 55%), 
and that they intervened at a hemoglobin concentration of less than 11 g/dl (C, 15%). Overlapping areas correspond to the 
proportion of participants whose responses fulfilled two adjacent or all three criteria (white, 11%); the two blue areas corre-
spond to less than 1% each. The bottom panel shows the proportion of respondents who indicated that secondary hyperpar-
athyroidism is a complication of CKD (A, 79%), that they screened starting in stage 3 CKD or earlier (B, 29%), and that they 
intervened at an intact PTH concentration of more than 70 pg/ml (C, 58%). Overlapping areas correspond to the proportion of 
participants whose responses fulfilled two adjacent or all three criteria (white, 15%).BMC Medicine 2006, 4:30 http://www.biomedcentral.com/1741-7015/4/30
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The use of mathematical formulas to estimate GFR rather
than a timed urine collection for creatinine clearance is
recommended for most patients [40], and the examina-
tion of a random urine sample for albumin and creatinine
is the preferred screening method for albuminuria in
adults [7,27]. However, despite this, more than half the
physicians preferred a timed urine collection for creati-
nine, and in a hypothetical patient with diabetes and stage
3 CKD, only 70% of physicians elected to screen for
microalbuminuria. Moreover, among those who did
screen for microalbuminuria, only about a third would
concomitantly obtain a urine creatinine concentration to
normalize the albumin result (family medicine trainees:
19%, internal medicine trainees: 37%), as recommended
by both the NKF and ADA [27,41]. Thus, further emphasis
may need to be placed on hands-on implementation of
clinical practice guidelines to improve the detection of
subjects with CKD.
The vast majority of respondents identified blood pres-
sure goal and first line antihypertensive agents for patients
with CKD as recommended by the Seventh Report of the
Joint National Committee on Prevention, Detection, Eval-
uation, and Treatment of High Blood Pressure [42]. How-
ever, practitioners, and in particular family medicine
residents, were hesitant to use ACEi in the setting of stage
3 or 4 CKD. Data supporting the use of ACEi and ARB
show that these agents are not only beneficial in patients
with an abnormal serum creatinine, but also safe, as long
as patients are carefully monitored and counseled [43,44].
Thus, it may be necessary to not only disseminate infor-
mation about the usefulness of a given intervention, but
also hands-on information about monitoring, preven-
tion, and treatment of potential complications.
Almost all physicians recognized worsening hyperten-
sion, anemia, hyperkalemia, volume overload, and meta-
bolic acidosis as complications of CKD. However,
secondary hyperparathyroidism, malnutrition, and lipid
disorders were identified by a significantly smaller pro-
portion of respondents. Moreover, even though about
90% of physicians recognized anemia as a complication
of CKD, only about 40% indicated that they would obtain
a CBC in a hypothetical patient with diabetes and an eGFR
of 34 ml/min/1.73 m2. Similarly, even among those who
identified secondary hyperparathyroidism as a CKD com-
plication, only a small fraction would order the appropri-
ate screening test. This reflects the observation that the
majority of patients with stage 4 CKD referred to a neph-
rologist were never screened for secondary hyperparathy-
roidism and had lower hemoglobin concentrations than
those seen in a dedicated CKD clinic for at least six
months [45]. In addition, the management of anemia and
secondary hyperparathyroidism requires complex deci-
sion-making. These disorders have not only to be recog-
nized as a complication of CKD, but in order to avoid
future complications, screening needs to be initiated in
stage 3 CKD and physicians also need to know about rec-
ommended treatment targets in order to either initiate
therapy or consult an experienced specialist [9,12]. The
data from this survey show that no more than 10% of phy-
sicians had the skills to integrate data from all three areas
correctly, allowing them to formulate appropriate man-
agement plans for CKD patients with anemia or secondary
hyperparathyroidism. Thus, unless an educational effort
aimed specifically at non-nephrologists fills these knowl-
edge gaps, nephrologists will likely have to co-manage
patients with stage 3 and 4 CKD.
Clinical practice guidelines may present treatment goals,
but often lack the necessary guidance as to why and how
to reach these goals. Recently, an approach to link evi-
dence with practice in CKD care, which may be particu-
larly useful in managed care settings, has been published
[46]; however, none of the strategies to improve compli-
ance tested thus far have proven fail-safe [47]. Deficits in
compliance with clinical practice guidelines are not
unique to nephrology, and the reasons for non-compli-
ance are complex [48]. Recent data show that there is an
acute lack of awareness of clinical practice guidelines for
CKD patients among primary providers [22,49]. Based on
the data presented here, educational efforts aimed at
improving CKD care will have to start during the training
program, even though this may be a challenging under-
taking given the requirements and restrictions placed
upon US training programs [50]. Specifically, trainees will
need to be instructed about prevalence of CKD, risk fac-
tors for CKD, screening methods for CKD and its compli-
cations, and treatment options to slow the progression of
CKD and reduce morbidity and mortality [51-54]. In
order to succeed, guidelines will have to be presented in a
manner that fosters reflection, critically appraises clinical
evidence, is practice-based, and is easy to understand for
practitioners and patients alike [48,55].
This study has several important limitations. Given that it
is based on a voluntary, anonymous online survey, certain
important variables, such as training program size and set-
ting, or the presence or absence of formal teaching in CKD
care, cannot be controlled. In addition, demographic
characteristics of the study cohort cannot be verified.
Finally we cannot be certain that the answers truly reflect
the knowledge of the person completing the survey, given
that the survey instrument has not been formally vali-
dated in this respect, although we did include nephrolo-
gists who might serve as a positive control group (see
Additional file 2). However, given that we received a large
number of responses from across the United States, we
believe that the data presented here are representative andBMC Medicine 2006, 4:30 http://www.biomedcentral.com/1741-7015/4/30
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covey important information about practice patterns of
future providers.
Conclusion
In conclusion, the results from this survey suggest that
physicians currently in training have significant knowl-
edge gaps in CKD management, and with few exceptions
attendings' responses closely mimicked those of trainees.
These finding suggests that education is needed to raise
awareness of clinical practice guidelines and recommen-
dations for patients with CKD among future practitioners.
Surveys similar to ours may be useful in the planning of
training programs to assess areas that need additional
emphasis.
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